Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.
- DOI
- 10.3389/fped.2024.1392644
- Published
- 2024
- Container
- Frontiers in pediatrics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fped.2024.1392644,
title = {Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.},
author = {Frishberg Y and Hayes W and Shasha-Lavsky H and Sas DJ and Michael M and Sellier-Leclerc AL and Hogan J and Willey R and Gansner JM and Magen D},
year = {2024},
journal = {Frontiers in pediatrics},
doi = {10.3389/fped.2024.1392644},
url = {https://doi.org/10.3389/fped.2024.1392644}
}RIS
TY - JOUR TI - Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial. AU - Frishberg Y AU - Hayes W AU - Shasha-Lavsky H AU - Sas DJ AU - Michael M AU - Sellier-Leclerc AL AU - Hogan J AU - Willey R AU - Gansner JM AU - Magen D PY - 2024 JO - Frontiers in pediatrics DO - 10.3389/fped.2024.1392644 UR - https://doi.org/10.3389/fped.2024.1392644 ER -
APA
Y, F., W, H., H, S., DJ, S., M, M., AL, S., J, H., R, W., JM, G., & D, M. (2024). Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 30-month analysis of the phase 3 ILLUMINATE-B trial.. Frontiers in pediatrics. https://doi.org/10.3389/fped.2024.1392644
Source records
- pubmed · retrieved 2026-09-25T05:29:37.252Z